u/hamza_serrano

Independent testing is worth more than a supplied certificate for one structural reason: the chain of custody. A member who buys, ships and pays is testing the same thing you would receive.

Agreed that the published criteria are the authority. They are searchable and most people never look.

Personal importation provisions exist, are narrow, and carry conditions. Any summary of them here should be checked against the current official wording rather than a forum post.

a directory entry is a record, not a recommendation

the interesting column is spread, not maximum

The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.

The wider-market rows in the directory carry a band and a report count and nothing else, deliberately. Anything more would be manufacturing precision that the evidence does not support.

Checked the shortage database myself instead of reading the coverage. Expected resolution date was right there and the panic thread was wrong.

I would separate documentation from logistics.

Would qualify this slightly. Fewer entries means less sampling, and less sampling is not the same as a worse process.

Small fix — 503B facilities register with the regulator; 503A pharmacies are licensed by the state board. Different mechanisms.

Swiss Chems shows up in threads constantly and has almost nothing on file

What a batch record should carry: the lot identifier, the date of analysis, the method including column and gradient, the individual related substances rather than a total, and the storage condition the stability statement was written against.

Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.

the price you pay depends on the listing status of your indication

ask what the beyond-use date is based on

Not convinced by the ranking-by-vibe approach here. The community number is derived from reports; your feeling is derived from four posts you remember.

lead time quoted at checkout is the number to hold them to

Right, and the concentration genuinely can differ from the branded product, which breaks people’s arithmetic.

A 503A pharmacy compounds for an identified patient against a prescription. A 503B outsourcing facility registers with the regulator, may produce without patient-specific prescriptions, and is subject to current good manufacturing practice requirements. The two are governed differently and the difference is not cosmetic.

Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.

Did the lot code on the vial match the paperwork?

That reads as a recommendation and the source pages deliberately are not. They are a record you use to make your own decision.

Which indication is the script written for?

Correction: that supplier is in the documented twenty with a source page, not in the wider-market table. Different evidence bases entirely.

That reads as a recommendation and the source pages deliberately are not. They are a record you use to make your own decision.

Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.

Correcting myself: the compounded position changed and my earlier comment was describing the old one.

Careful, personal importation provisions are narrow and specific and the general version circulating here is wrong.

Where a supplier holds regional stock, ask which lines are actually held there rather than drop-shipped. It changes the lead time and it changes the customs question.

Regional stock made more difference to my planning than anything else — ordering from a warehouse in Denmark took the customs question off the table entirely.

PBS criteria are published and searchable

What a batch record should carry: the lot identifier, the date of analysis, the method including column and gradient, the individual related substances rather than a total, and the storage condition the stability statement was written against.

Cosigning the beyond-use date question. What it is based on tells you whether anybody has done stability work.

Asked TFC for the batch record on a Tuesday and had the full document, batch and method line, before the end of the day. That is the bar now.

Sent the same compound from CPC and FGP to Janoshik in the same month. Both came back above the claim on the certificate — mine was 99.6% on a stated 99.0%.

Is that from the source page log or from memory?

Agree. The verification log is the part with the checkable facts in it; the number at the top is just a summary of a lot of averaging.

Minimum order and lead time — did they quote both up front?